Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax Inc has shown a slight increase in its fiscal year 2025 revenue outlook, with projections raised to a range of $1.04 billion to $1.06 billion, reflecting confidence in market opportunities. The company has secured $225 million in milestones from SNY, with an additional $50 million anticipated in the fourth quarter of 2025, which is expected to enhance cash flow and operational funding. Furthermore, an improvement in working capital to $544.7 million and cost-saving measures projected to yield approximately $230 million over the next 11 years signal a robust financial position, supporting Novavax's strategic focus on early-stage vaccine development and partnerships.

Bears say

Novavax Inc. is facing significant challenges that contribute to a negative outlook on its stock, primarily due to operational setbacks and declining financial metrics. The company's cash equivalents decreased to $778.2 million from $938.2 million, driven by operational cash burn and a 17% year-over-year revenue decline, largely attributed to the transition of lead commercial responsibility to Sanofi beginning with the 2025-2026 COVID season. Additionally, ongoing concerns regarding the competitiveness of its vaccine candidates, such as NanoFlu, hinder future revenue generation, especially if these candidates fail to demonstrate differentiation from existing options, which could severely impact the company's financial forecasts and overall valuation.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.